• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Medicaid waiver program helped public hospitals improve care to California ’s most needy
A five-year Medicaid waiver program that infused billions of dollars into public hospitals prompted significant improvements in health care to California ’s neediest population — the poor and uninsured, according to an extensiveevaluation by the UCLA Center for Health Policy Research.Seventeen designated public hospitals participated in the $3.3 billion “pay-for-performance” experiment, including five University of California hospital systems and 12 county‐owned-and‐operated hospital systems. Collectively, these facilities serve more than 2 million patients every year, including most of the state’s Medi-Cal p...
Source: UCLA Newsroom: Health Sciences - June 28, 2017 Category: Universities & Medical Training Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news